Next-Generation Biomanufacturing Market Outlook:
Next-Generation Biomanufacturing Market size was over USD 25.71 billion in 2025 and is projected to reach USD 57.6 billion by 2035, growing at around 8.4% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of next-generation biomanufacturing is evaluated at USD 27.65 billion.
The enormous expansion in biologics and biosimilars in recent years has increased the need for biomanufacturing technologies. As per a report, currently, the development of biologics accounts for around 40% of all pharmaceutical R&D spending. It is essential to advancing healthcare since it provides cutting-edge cures and treatments. Additionally, biomanufacturing accelerates scientific research, boosts economic growth, and provides jobs. Because it promotes the creation of environmentally friendly technology and lowers industrial waste, its importance goes beyond environmental preservation. The advantages of biomanufacturing include its affordability, scalability, and potential for growth.
Furthermore, businesses that are adopting next-generation biomanufacturing can collaborate with organizations like Danaher Corporation's life sciences divisions to create adaptable, novel processes for every phase of production, from research and development to cGMP manufacturing. The array of flexible manufacturing services and products is expanding quickly, providing pharmaceutical companies with multiple choices to maximize the production of genetically modified medications.
